Search
baxdrostat
Indications:
- treatment resistant hypertension (investigational)
Dosage:
- 0.5, 1 or 2 mg QD
Adverse effects:
- hyperkalemia
Mechanism of action:
- selective aldosterone antagonist
- reductions in systolic blood pressure of 20 mm Hg with 2 mg dose, 18 mm Hg with 1 mg dose & 12 mm Hg with 0.5 mg dose [1]
Interactions
drug adverse effects of renin-angiotensin-aldosterone system inhibitors (RAAS inhibitors)
General
aldosterone receptor antagonist (aldosterone antagonist)
References
- Freeman MW, Halvorsen YD, Marshall W et al
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
N Engl J Med 2022. Nov 7
PMID: 36342143
https://www.nejm.org/doi/10.1056/NEJMoa2213169